Approximately 5% of patients with NSCLC have ALK-positive disease.[1–4] ALK-positive NSCLC patients are younger, in their 50s, nonsmokers, and more likely to be diagnosed with more advanced disease than those with ALK-negative NSCLC.[2,4–6] ALK inhibitors are the first-line agents in chemotherapy for ALK-positive lung cancer.[7–10] The treatment of lung cancer has been revolutionized by the advent of ICIs. The gene discussed is ALK; the disease is lung carcinoma.